Device manufacturer, as written on reports
Bd: medical device reports filed with FDA
2,086 reports name it as the manufacturer of the device involved, 2000–2025.
- 2,086
- reports naming it as manufacturer
- 0% of all MAUDE reports
- 4
- reports, 12 months to August 2026
- 64 in the 12 months before
- 54%
- classified as malfunction
- 62.3% across all reports
- 0.5%
- classified as death, as reported
- 0.9% across all reports
2,086 medical device reports received by FDA give Bd as the manufacturer of the device involved, 0% of the MAUDE database, from August 2000 to October 2025. Manufacturer names are as written on the report; subsidiaries and spelling variants may appear as separate names.
4 reports arrived in the 12 months to August 2026, down 94% from 64 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (54%), injury (36.4%) and other (6.1%). Manufacturers are required to report events they learn of, so a large manufacturer with many products in use files many reports. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Brands named most often
| Brand | Device type | Reports | Latest 12 months | Classified as death |
|---|---|---|---|---|
| Bd | Syringe, piston | 79 | 0 | 1% |
| BD Insyte Autoguard | Catheter, intravascular, therapeutic, short-term less than 30 days | 23 | 55 | 0% |
| Insyte AUTOGUARD | Catheter, intravascular, therapeutic, short-term less than 30 days | 22 | 1,050 | 0% |
| BD alaris pump infusion set | Set, administration, intravascular | 14 | 55 | 1.1% |
| BD Nexiva | Catheter, intravascular, therapeutic, short-term less than 30 days | 13 | 14 | 0% |
| Nexiva | Catheter, intravascular, therapeutic, short-term less than 30 days | 13 | 304 | 0% |
| Bd Ultra Fine Pen Needle | Needle, hypodermic, single lumen | 11 | 0 | 0% |
| Bd Plastipak Syringes | Syringe, piston | 5 | 0 | 0.5% |
| Bd Safetyglide Needle | Needle, hypodermic, single lumen | 5 | 3 | 0% |
| BD Vacutainer Eclipse Blood Collection Needle | Needle, hypodermic, single lumen | 5 | 627 | 0% |
| Alaris, SmartSite | Set, administration, intravascular | 4 | 316 | 0.1% |
| Bd Insulin Syringe With Bd Ultra-Fine Needle | Syringe, piston | 4 | 0 | 0% |
| Bd Precisionglide Needle | Needle, hypodermic, single lumen | 4 | 0 | 0% |
| Bd Luer-Lok Tip Syringe | Syringe, piston | 3 | 0 | 0% |
| BD Vacutainer Push Button Blood Collection Set | Tubes, vials, systems, serum separators, blood collection | 3 | 324 | 0% |
| Alaris | Pump, infusion | 2 | 79 | 1.1% |
| BD Syringe | Syringe, piston | 2 | 117 | 0.4% |
| Eclipse | System, planning, radiation therapy treatment | 2 | 44 | 0.7% |
| Luer-Lok | Syringe, piston | 2 | 256 | 0% |
| Relion Insulin Syringe | Syringe, piston | 2 | 0 | 0% |
| Smartsite Extension Set | Set, administration, intravascular | 2 | 0 | 0.3% |
| Alaris Pca Module | Pump, infusion | 1 | 0 | 3.1% |
| Bd 60ml Syringe Luer-Lok Tip | Syringe, piston | 1 | 0 | 0% |
| Bd Eclipse Needle | Needle, hypodermic, single lumen | 1 | 1 | 0% |
| Bd Insyte | Catheter, intravascular, therapeutic, short-term less than 30 days | 1 | 0 | 0% |
| First Picc | Catheter, intravascular, therapeutic, short-term less than 30 days | 1 | 0 | 0.4% |
Brands with a page on this site, ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Device types
| Product code | Device type | Reports | Share |
|---|---|---|---|
| FMI | Needle, hypodermic, single lumen | 545 | 26.1% |
| FMF | Syringe, piston | 493 | 23.6% |
| FOZ | Catheter, intravascular, therapeutic, short-term less than 30 days | 461 | 22.1% |
| FPA | Set, administration, intravascular | 195 | 9.3% |
| JKA | Tubes, vials, systems, serum separators, blood collection | 155 | 7.4% |
| QKP | Coronavirus antigen detection test system. | 63 | 3% |
| NGT | Saline, vascular access flush | 51 | 2.4% |
| GES | Blade, scalpel | 38 | 1.8% |
| FMG | Stopcock, i.v. set | 35 | 1.7% |
| LJS | Catheter, intravascular, therapeutic, long-term greater than 30 days | 33 | 1.6% |
Reports by month, five years
FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
Event type
Grey bar: all 26,136,888 MAUDE reports. Event type is the filer's classification and is not verified by FDA.
Questions about Bd reports
How many FDA device reports name Bd as manufacturer?
2,086 reports through August 2026, 4 of them in the latest 12 months.
Which of its brands appear most often?
Bd (79), BD Insyte Autoguard (23), Insyte AUTOGUARD (22), BD alaris pump infusion set (14) and BD Nexiva (13).
Which device types does it report on?
needle, hypodermic, single lumen (26.1%), syringe, piston (23.6%), catheter, intravascular, therapeutic, short-term less than 30 days (22.1%) and set, administration, intravascular (9.3%).
Does a high count say something about the manufacturer?
Not by itself. Manufacturers must file a report for every event they become aware of, so report volume follows the number of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. Manufacturer names are pooled after company suffixes (Inc., LLC, GmbH and similar) are dropped; names that read as a person rather than an organisation are never published. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.